7 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

This week, Emergent BioSolutions Inc.’s (EBS) ratings are up from a B last week to a A. Emergent BioSolutions Inc. develops and produces immunobiotics, pharmaceutical products that assist the body’s immune system to prevent or treat disease. The company also gets A’s in operating margin growth, earnings growth, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of EBS stock.

This week, MacroGenics, Inc. (MGNX) pushes up from a C to a B rating. The company also gets A’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of MGNX stock.

Forward Pharma A/S Sponsored ADR (FWP) is seeing ratings go up from a C last week to a B this week. The company also gets A’s in earnings surprise. For more information, get Portfolio Grader’s complete analysis of FWP stock.

OPKO Health, Inc.’s (OPK) ratings are looking better this week, moving up to a B from last week’s C. OPKO Health, Inc. is involved in the discovery, development, and commercialization of pharmaceutical products, vaccines, and diagnostic products. The company also gets A’s in sales growth and earnings surprise. For more information, get Portfolio Grader’s complete analysis of OPK stock.

Chemocentryx, Inc. (CCXI) boosts its rating from a C to a B this week. Chemocentryx, Inc. a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. For more information, get Portfolio Grader’s complete analysis of CCXI stock.

Minerva Neurosciences Inc (NERV) earns a B this week, jumping up from last week’s grade of C. The company also gets A’s in earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of NERV stock.

Curis, Inc. (CRIS) gets a higher grade this week, advancing from a C last week to a B. Curis, Inc. is a drug discovery and development company that engages in the research and development of cancer therapeutics. For more information, get Portfolio Grader’s complete analysis of CRIS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.